Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.12), $0.30 better than the analyst estimate of ($1.42). Revenue for the quarter came in at $66.76 million versus the consensus estimate of $2.01 million.

2025 Financial Guidance

The company is maintaining its full year 2025 financial guidance:

GAAP operating expense* $670 million to $710 million
Non-cash stock-based compensation expense included in GAAP operating expense $120 million to $110 million

*GAAP operating expense comprised of R&D and SG&A expenses.

Anticipated year-over-year increase in GAAP operating expense includes investments toward commercial readiness for the potential approval and launch of aficamten for patients with obstructive HCM.

The financial guidance does not include the effect of GAAP adjustments as may be caused by events that occur subsequent to publication of this guidance, including but not limited to Business Development activities.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.